Highlights
- Market Cap
- $203.42M
- Enterprise Value
- $116.00M
- EPS (TTM)
- $1.43
- PE Ratio
- 1.18
- PEG Ratio
- 0.01
- Total Revenue (TTM)
- $42.17M
- Gross Profit (TTM)
- -$15.74M
- EBITDA (TTM)
- -$172.88M
- Year Range
- $0.71 - $2.62
- Target Price
- $6.02
- ROA (TTM)
- 65.04%
- ROE (TTM)
- 275.39%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Coherus BioSciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Coherus BioSciences, Inc. (CHRS) has returned 19.01% so far this year and 109.42% over the past 12 months. Over the last ten years, CHRS has returned -22.80% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Coherus BioSciences, Inc.
- 1D
- 5.62%
- 1M
- 1.20%
- YTD
- 19.01%
- 6M
- 3.05%
- 1Y
- 109.42%
- 3Y*
- -37.25%
- 5Y*
- -34.99%
- 10Y*
- -22.80%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Nov 6, 2014, CHRS's average daily return is +0.04%, while the average monthly return is +0.62%. At this rate, your investment would double in approximately 9.3 years.
Historically, 49% of months were positive and 51% were negative. The best month was Nov 2024 with a return of +63.8%, while the worst month was May 2023 at -43.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, CHRS closed higher 47% of trading days. The best single day was Nov 20, 2024 with a return of +33.9%, while the worst single day was Nov 7, 2023 at -30.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 52.11% | -22.69% | 1.20% | 19.01% | |||||||||
| 2025 | -14.49% | -5.93% | -27.30% | 27.63% | -24.37% | -6.12% | 28.57% | 23.38% | 41.38% | 2.44% | -19.05% | 4.41% | 2.90% |
| 2024 | -35.44% | 6.05% | 4.82% | -17.99% | -7.14% | -4.95% | -10.98% | -9.74% | -25.18% | -28.37% | 63.76% | 13.11% | -58.56% |
| 2023 | 7.07% | -20.17% | 1.03% | 5.70% | -43.43% | 4.40% | 12.88% | 10.58% | -29.83% | -10.43% | -36.42% | 56.34% | -57.95% |
| 2022 | -22.56% | -4.61% | 9.50% | -29.98% | -18.81% | -1.36% | 16.99% | 32.00% | -14.04% | -9.47% | -21.15% | 15.45% | -50.38% |
| 2021 | 8.17% | -13.62% | -10.04% | 1.30% | -11.08% | 5.09% | -5.64% | 22.45% | 0.56% | 4.11% | 11.00% | -14.05% | -8.17% |
Benchmark Metrics
Coherus BioSciences, Inc. has an annualized alpha of -5.98%, beta of 1.39, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since November 07, 2014.
- This stock participated in 132.00% of S&P 500 Index downside but only 14.98% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -5.98%
- Beta
- 1.39
- R²
- 0.11
- Upside Capture
- 14.98%
- Downside Capture
- 132.00%
Return for Risk
Risk / Return Rank
CHRS ranks 77 for risk / return — better than 77% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and compare them to a chosen benchmark (S&P 500 Index).
| CHRS | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.25 | 0.90 | +0.35 |
Sortino ratioReturn per unit of downside risk | 1.99 | 1.39 | +0.60 |
Omega ratioGain probability vs. loss probability | 1.24 | 1.21 | +0.03 |
Calmar ratioReturn relative to maximum drawdown | 2.57 | 1.40 | +1.17 |
Martin ratioReturn relative to average drawdown | 4.61 | 6.61 | -1.99 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore CHRS risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Coherus BioSciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Coherus BioSciences, Inc. was 98.21%, occurring on Nov 4, 2024. The portfolio has not yet recovered.
The current Coherus BioSciences, Inc. drawdown is 95.49%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.21% | Jul 23, 2015 | 2338 | Nov 4, 2024 | — | — | — |
| -35.86% | Mar 3, 2015 | 48 | May 8, 2015 | 43 | Jul 10, 2015 | 91 |
| -17.86% | Feb 10, 2015 | 5 | Feb 17, 2015 | 7 | Feb 26, 2015 | 12 |
| -16.38% | Nov 11, 2014 | 28 | Dec 19, 2014 | 4 | Dec 26, 2014 | 32 |
| -11.46% | Jan 15, 2015 | 6 | Jan 23, 2015 | 4 | Jan 29, 2015 | 10 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Coherus BioSciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Coherus BioSciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CHRS, comparing it with other companies in the Biotechnology industry. Currently, CHRS has a P/E ratio of 1.2. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CHRS compared to other companies in the Biotechnology industry. CHRS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CHRS relative to other companies in the Biotechnology industry. Currently, CHRS has a P/S ratio of 4.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CHRS in comparison with other companies in the Biotechnology industry. Currently, CHRS has a P/B value of 3.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |